Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 9, 2026, 11:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Thinning Hair Clear all
Completed Phase 1 Interventional

Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions

NCT02124239
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Ingenol mebutate
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Jun 9, 2026, 11:55 PM EDT
Recruiting Phase 3 Interventional

A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

NCT07029828
View directory record Official record
Conditions
Severe Alopecia Areata
Interventions
Ritlecitinib higher dose, Ritlecitinib lower dose
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 14 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
18
States / cities
Encinitas, California • Miami, Florida • Tamarac, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jun 9, 2026, 11:55 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia

NCT02279823
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
CB-03-01 solution, Minoxidil Solution 5%, Placebo solution
Drug
Lead sponsor
Intrepid Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
San Diego, California • Fridley, Minnesota • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Jun 9, 2026, 11:55 PM EDT
Completed Phase 2 Interventional Results available

A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution

NCT03495817
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
ATI-50002
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Denver, Colorado • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Jun 9, 2026, 11:55 PM EDT
Not listed Not applicable Interventional

Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia

NCT01831024
View directory record Official record
Conditions
Chemotherapy Adjuvant, Breast Cancer
Interventions
Dignicap System
Device
Lead sponsor
Target Health Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
San Francisco, California • New York, New York • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Jun 9, 2026, 11:55 PM EDT
Recruiting Phase 1 Interventional

HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata

NCT07049328
View directory record Official record
Conditions
Alopecia Areata(AA)
Interventions
HCW9302, an IL-2 fusion protein
Drug
Lead sponsor
HCW Biologics
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Tampa, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jun 9, 2026, 11:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

LLLT for Alopecia of the Eyebrow in Women

NCT04897555
View directory record Official record
Conditions
Alopecia
Interventions
LLLT
Device
Lead sponsor
Freedom Laser Therapy, Inc.
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Mendham, New Jersey • Great Neck, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Jun 9, 2026, 11:55 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Non-Ablative Laser to Treat Scarring Alopecia With Hair Follicle Gene Expression Analysis

NCT06946550
View directory record Official record
Conditions
Scarring Alopecia
Interventions
1470nm non-ablative fractional laser
Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Elmsford, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jun 9, 2026, 11:55 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males

NCT02781311
View directory record Official record
Conditions
Alopecia
Interventions
Setipiprant, Placebo, Finasteride
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
18
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Jun 9, 2026, 11:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling

NCT04341363
View directory record Official record
Conditions
Androgenic Alopecia
Interventions
Tattoo machine
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Jun 9, 2026, 11:55 PM EDT
Terminated Phase 2 Interventional Results available

PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA

NCT04517864
View directory record Official record
Conditions
Alopecia Areata
Interventions
PF-06651600, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
23
States / cities
Huntington Beach, California • Irvine, California • Boca Raton, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jun 9, 2026, 11:55 PM EDT
Recruiting Phase 2 Interventional

Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome

NCT07242638
View directory record Official record
Conditions
Atopic Dermatitis, Alopecia Areata
Interventions
Abrocitinib
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jun 9, 2026, 11:55 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

A Safety and Efficacy Study of a Nutraceutical in Aging Males With Thinning Hair

NCT06854575
View directory record Official record
Conditions
Hair Thinning
Interventions
Dietary Supplement, Placebo
Dietary Supplement · Other
Lead sponsor
Nutraceutical Wellness Inc.
Industry
Eligibility
40 Years to 65 Years · Male only
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
3
States / cities
Phoenix, Arizona • Elizabeth, New Jersey • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Jun 9, 2026, 11:55 PM EDT
Completed Phase 1 Interventional

Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia

NCT02848300
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Bimatoprost 1% Formulation A, Bimatoprost 1% Formulation B
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Jun 9, 2026, 11:55 PM EDT
Not listed Phase 4 Interventional

Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia

NCT03422640
View directory record Official record
Conditions
Frontal Fibrosing Alopecia
Interventions
Apremilast
Drug
Lead sponsor
Bellevue Dermatology
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Jul 15, 2018 · Synced Jun 9, 2026, 11:55 PM EDT
Completed Early Phase 1 Interventional

A Clinical Comparison of FDA-Cleared Photobiomodulation Devices for the Treatment of Alopecia

NCT06748287
View directory record Official record
Conditions
Alopecia
Interventions
iGrow Hair Growth System, Capillus352, HairMax Ultima 12 Lasercomb, HairMax Laserband 82
Device
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years to 85 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Jun 9, 2026, 11:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pain Outcomes Following Intralesional Corticosteroid Injections

NCT03630198
View directory record Official record
Conditions
Keloid, Alopecia Areata, Acne, Hypertrophic Scar, Epidermal Inclusion Cyst, Frontal Fibrosing Alopecia, Lichen Plano-Pilaris, Keratoacanthoma, Plaque Psoriasis, Lichen Simplex Chronicus, Prurigo Nodularis, Nummular Eczema, Granuloma Annulare, Morphea, Lichen Planus
Interventions
Corticosteroid with lidocaine, Corticosteroid with normal saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Jun 9, 2026, 11:55 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss

NCT05910450
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
Clascoterone 5% solution, Vehicle solution
Drug
Lead sponsor
Cassiopea SpA
Industry
Eligibility
18 Years and older · Male only
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
16
States / cities
North Little Rock, Arkansas • San Diego, California • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 9, 2026, 11:55 PM EDT
Completed Phase 2 Interventional Results available

LEO 124249 Ointment in the Treatment of Alopecia Areata

NCT02561585
View directory record Official record
Conditions
Alopecia Areata
Interventions
LEO 124249, Vehicle
Drug · Other
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Evanston, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Jun 9, 2026, 11:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

NCT02100813
View directory record Official record
Conditions
Actinic Keratosis
Interventions
LEO 43204, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Snellville, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Jun 9, 2026, 11:55 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

NCT03811912
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543, CTP-543 Matching Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
10
States / cities
Irvine, California • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Jun 9, 2026, 11:55 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata

NCT06444451
View directory record Official record
Conditions
Alopecia Areata
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
17
States / cities
Birmingham, Alabama • Fountain Valley, California • Fremont, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jun 9, 2026, 11:55 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial in Females for Female Pattern Hair Loss

NCT01226459
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
5% Minoxidil Topical Foam, Vehicle Topical Foam
Drug
Lead sponsor
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Wichita, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Jun 9, 2026, 11:55 PM EDT
Recruiting No phase listed Observational

CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry

NCT06562270
View directory record Official record
Conditions
Alopecia Areata
Interventions
Not listed
Lead sponsor
CorEvitas
Network
Eligibility
12 Years to 17 Years
Enrollment
1,500 participants
Timeline
2024 – 2099
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jun 9, 2026, 11:55 PM EDT